EUCTR2017-001755-31-DE进行中（未招募）1 期
Randomized Phase-II Study of Trabectedin/Olaparib Compared to Physician’s Choice in Subjects with Previously Treated Advanced or Recurrent Solid Tumors Harboring DNA Repair Deficiencies - NCT-PMO1603 TOP-ART
Ruprecht-Karls-Universität Heidelberg, Medical Faculty0 个研究点目标入组 108 人开始时间: 2018年3月22日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 108
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Provision of a written informed consent
- •2.Patients is able to understand and comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations
- •3.Progressive locally advanced or metastatic malignancy as determined by local investigator.
- •4.At least one measurable lesion that can be accurately assessed at baseline by CT or MRI and is suitable for repeated assessment
- •5.Prior administration of at least one standard treatment for primary and/or relapsed malignancy according to current guidelines
- •6.Eastern Cooperative Oncology Group Performance Status = 1
- •7.Patients with central venous access device in place (central venous catheter or port-a-cath)
- •8.Male or female patient aged = 18 and = 70 years
- •9.Postmenopausal or evidence of non-childbearing status. For women of childbearing potential: negative urine or serum pregnancy test within 14 days prior to study treatment and highly effective forms of contraception in place thereafter as well as confirmed negative urine or serum pregnancy test prior to treatment on day 1 of every cycle
- •Postmenopausal or evidence of non-childbearing status is defined as:
- •oAmenorrheic for 1 year or more following cessation of exogenous hormonal treatments
- •oLuteinizing hormone (LH) and Follicle stimulating hormone (FSH) levels in the post menopausal range for women under 50 except in patients with a history of surgical sterilisation (bilateral oophorectomy or hysterectomy)
- •oRadiation-induced oophorectomy with last menses >1 year ago
- •oChemotherapy-induced menopause with >1 year interval since last menses
- •oSurgical sterilisation (bilateral oophorectomy or hysterectomy)
- •10.Female patients of child bearing potential and male patients with partners of child bearing potential, who are sexually active, must agree to the use of highly effective forms of contraception. This should be started from the signing of the informed consent and continue throughout period of taking study treatment and for 1 month (female patients) / 3 months (male patients) after last dose of study drug.
- •11.Identification of defective DNA repair via Homologous Recombination, as determined by molecular analysis within NCT/DKTK MASTER (Heidelberg Ethics Committee Reference No.: S-206/2011). Eligibility for the study is defined by the molecular tumorboard of NCT on the basis of whole-exome/genome sequencing and the presence of genomic markers for BRCAness”.
- •12.Adequate bone marrow, renal, and hepatic function defined by laboratory tests within 14 days prior to study treatment:
- •oHemoglobin = 10 g/dl
- •oNeutrophil count = 1,500/mm3
- •oPlatelet count = 100,000/µl
- •oBilirubin = 1.0 x upper limit of normal (ULN)
- •oALT and AST = 2.5 x ULN
- •oAlkaline phosphatase = 2.5 x ULN
- •oPT-INR/PTT = 1.5 x ULN
- •oAlbumin = 25 g/l
- •oCreatine kinase = 2.5 x ULN
- •oSerum creatinine ? 1.5 mg/dl or creatinine clearance ? 51 ml/min (calculation according to Crockroft-Gault)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 90
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 18
排除标准
- •1.Hematological malignancies and primary brain tumors. Patients with known progressive brain metastases determined by serial imaging or declining neurologic function in the opinion of the treating physician are not eligible. Patients with symptomatic uncontrolled brain metastases and patients with symptomatic uncontrolled spinal cord compression are not eligible. Patients with previously treated brain metastases are eligible, provided that the patient has not experienced a seizure or had a clinically significant change in neurological status within the three months prior to enrollment. All patients with previously treated brain metastases must be clinically stable for at least 1 month after completion of treatment and off steroid treatment for one month, both prior to study enrollment
- •2.Other malignancy within the last 5 years except: adequately treated non-melanoma skin cancer, curatively treated in situ cancer of the cervix, ductal carcinoma in situ (DCIS), Stage 1, grade 1 endometrial carcinoma, or other solid tumours including lymphomas (without bone marrow involvement) curatively treated with no evidence of disease for =5 years
- •3.Concurrent or previous treatment within 4 weeks in another interventional clinical trial
- •4.Treated with an investigational anticancer therapy less than 4 weeks prior to study treatment. Inclusion may be possible after > five half-lifes of previous treatment after consultation with the coordinating investigator on a case by case decision.
- •5.Prior treatment with PARP inhibitors
- •6.Patients with platinum-refractory disease, defined as progressive disease during or immediately after treatment with platinum based chemotherapy
- •7.Persistent toxicity (=Grade 2 according to Common Terminology Criteria for Adverse Events [CTCAE] version 5.0) caused by previous cancer therapy, excluding alopecia
- •8.Clinical signs of active infection (>Grade 2 according to CTCAE version 5.0)
- •9.History of HIV infection and immunocompromised patients
- •10.Viral active or chronic hepatitis (HBV or HCV)
- •11.Dementia or significant impairment of cognitive state
- •12.Epilepsy requiring pharmacologic treatment
- •13.Pregnancy and breast feeding (women)
- •14.Inability to take oral medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication
- •15.Major surgery within 4 weeks of starting study treatment. Patients must have reco-vered from any effects of any major surgery.
- •16.Patients receiving any systemic chemotherapy or radiotherapy within 2 weeks prior to study treatment or a longer period depending on the defined characteristics of the agents used
- •17.Known hypersensitivity to any of the study drugs or other ingredients of the investigational medicinal products
- •18.Resting ECG with QTc > 450 msec on 2 or more time points within a 24 hour period or family history of long QT syndrome
- •19.Abnormal left ventricular ejection fraction, defined as ejection fraction of <50% on echocardiography
- •20.Heart failure NYHA III/IV
- •21.Severe obstructive or restrictive ventilation disorder
- •22.Concomitant use of known strong CYP3A inhibitors (eg. itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (eg. ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil). The required washout period prior to starting olaparib is at least five half-lifes.
- •23.Concomita
研究者
相似试验
进行中（未招募）
1 期
Clinical trial for patients with advanced, metastatic or unresectable soft tissue sarcomaAdvanced, metastatic or unresectable soft tissue sarcomaMedDRA version: 20.0Level: HLTClassification code 10041298Term: Soft tissue sarcomas histology unspecifiedSystem Organ Class: 100000004864EUCTR2018-004497-10-ITITALIAN SARCOMA GROUP126
进行中（未招募）
1 期
combination of trabectedin and olaparib in ovarian cancer, fallopian tubes and primary of peritoneum already resistant to standard platinum drugsplatinum-resistant ovarian carcinoma or Fallopian tubes or primary of peritoneumMedDRA version: 21.1Level: LLTClassification code 10033131Term: Ovarian carcinomaSystem Organ Class: 100000004864EUCTR2018-000230-35-ITFONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCCS66
进行中（未招募）
1 期
Clinical trial of trabectedin and low-dose radiation therapy in advanced/metastatic sarcomasCTIS2023-509215-81-00Asoc Grupo Espanol De Investigacion En Sarcomas72
进行中（未招募）
1 期
A PHASE II CLINICAL STUDY, ON TRABECTEDIN IN COMBINATION WITH PPARg AGONIST PIOGLITAZONE IN PATIENTS WITH ROUND CELL MYXOID LIPOSARCOMAS OR DEDIFFERENTIATED G1 OR G2 LIPOSARCOMAS WITH STABLE DISEASE IN TREATMENT WITH TRABECTEDIN ALONE.Patients with myxoid/round cell liposarcoma treated with at least 4 cycle of T alone with a stable disease at the last tumor evaluationMedDRA version: 20.0Level: SOCClassification code 10028395Term: Musculoskeletal and connective tissue disordersSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 20.0Level: HLTClassification code 10024628Term: Liposarcomas malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10073139Term: Round cell liposarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10073137Term: Myxoid liposarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-005626-29-ITIRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI10
进行中（未招募）
1 期
A clinical study to assess the efficacy of Trabectedin in advanced retroperitoneal leiomyosarcoma and in liposarcomaEUCTR2012-005428-14-ITItalian Sarcoma Group95